Switch to:
Also traded in: Argentina, Germany, Mexico, Sweden, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.23
AZN's Cash to Debt is ranked lower than
80% of the 779 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. AZN: 0.23 )
Ranked among companies with meaningful Cash to Debt only.
AZN' s Cash to Debt Range Over the Past 10 Years
Min: 0.2  Med: 2.29 Max: N/A
Current: 0.23
Equity to Asset 0.21
AZN's Equity to Asset is ranked lower than
93% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. AZN: 0.21 )
Ranked among companies with meaningful Equity to Asset only.
AZN' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.44 Max: 0.59
Current: 0.21
0.21
0.59
Interest Coverage 4.63
AZN's Interest Coverage is ranked lower than
82% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.94 vs. AZN: 4.63 )
Ranked among companies with meaningful Interest Coverage only.
AZN' s Interest Coverage Range Over the Past 10 Years
Min: 4.63  Med: 9.87 Max: 19.13
Current: 4.63
4.63
19.13
F-Score: 7
Z-Score: 1.49
M-Score: -2.31
WACC vs ROIC
7.25%
14.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 14.55
AZN's Operating margin (%) is ranked higher than
69% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.61 vs. AZN: 14.55 )
Ranked among companies with meaningful Operating margin (%) only.
AZN' s Operating margin (%) Range Over the Past 10 Years
Min: 8.19  Med: 29.04 Max: 38.09
Current: 14.55
8.19
38.09
Net-margin (%) 10.46
AZN's Net-margin (%) is ranked higher than
66% of the 732 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.89 vs. AZN: 10.46 )
Ranked among companies with meaningful Net-margin (%) only.
AZN' s Net-margin (%) Range Over the Past 10 Years
Min: 4.73  Med: 20.81 Max: 29.72
Current: 10.46
4.73
29.72
ROE (%) 16.48
AZN's ROE (%) is ranked higher than
78% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. AZN: 16.48 )
Ranked among companies with meaningful ROE (%) only.
AZN' s ROE (%) Range Over the Past 10 Years
Min: 5.9  Med: 37.06 Max: 45.52
Current: 16.48
5.9
45.52
ROA (%) 4.12
AZN's ROA (%) is ranked higher than
54% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. AZN: 4.12 )
Ranked among companies with meaningful ROA (%) only.
AZN' s ROA (%) Range Over the Past 10 Years
Min: 2.2  Med: 14.19 Max: 20.88
Current: 4.12
2.2
20.88
ROC (Joel Greenblatt) (%) 45.54
AZN's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.31 vs. AZN: 45.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AZN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 28.78  Med: 119.25 Max: 199.64
Current: 45.54
28.78
199.64
Revenue Growth (3Y)(%) -1.60
AZN's Revenue Growth (3Y)(%) is ranked lower than
71% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. AZN: -1.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AZN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -5.8  Med: 3.7 Max: 19.9
Current: -1.6
-5.8
19.9
EBITDA Growth (3Y)(%) -13.30
AZN's EBITDA Growth (3Y)(%) is ranked lower than
83% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. AZN: -13.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AZN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.6  Med: 10.1 Max: 24.8
Current: -13.3
-30.6
24.8
EPS Growth (3Y)(%) -21.30
AZN's EPS Growth (3Y)(%) is ranked lower than
82% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. AZN: -21.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AZN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.9  Med: 9.8 Max: 24.7
Current: -21.3
-48.9
24.7
GuruFocus has detected 5 Warning Signs with AstraZeneca PLC $AZN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AZN's 10-Y Financials

Financials (Next Earnings Date: 2017-02-02)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AZN Guru Trades in Q1 2016

Jeremy Grantham 408,300 sh (New)
PRIMECAP Management 13,084,275 sh (+1223.11%)
Dodge & Cox 26,049,650 sh (+121.19%)
Jim Simons 5,682,800 sh (+14.58%)
Manning & Napier Advisors, Inc 487,770 sh (+6.07%)
Ken Fisher 233,409 sh (+5.33%)
Murray Stahl 28,302 sh (+1.08%)
Francis Chou 13,000 sh (unchged)
John Hussman 2,000 sh (unchged)
NWQ Managers 506,785 sh (-1.83%)
Pioneer Investments 446,513 sh (-79.72%)
» More
Q2 2016

AZN Guru Trades in Q2 2016

David Dreman 1,321 sh (New)
Ken Fisher 338,979 sh (+45.23%)
Jeremy Grantham 587,200 sh (+43.82%)
Dodge & Cox 32,532,723 sh (+24.89%)
PRIMECAP Management 15,365,950 sh (+17.44%)
NWQ Managers 572,985 sh (+13.06%)
Jim Simons 5,966,100 sh (+4.99%)
Pioneer Investments 447,226 sh (+0.16%)
Manning & Napier Advisors, Inc 487,770 sh (unchged)
John Hussman 2,000 sh (unchged)
Murray Stahl 28,302 sh (unchged)
Francis Chou 13,000 sh (unchged)
» More
Q3 2016

AZN Guru Trades in Q3 2016

Andreas Halvorsen 4,175,587 sh (New)
Ken Fisher 1,977,585 sh (+483.39%)
NWQ Managers 839,815 sh (+46.57%)
Dodge & Cox 42,189,973 sh (+29.68%)
PRIMECAP Management 17,313,325 sh (+12.67%)
Manning & Napier Advisors, Inc 495,960 sh (+1.68%)
Jeremy Grantham 594,800 sh (+1.29%)
Francis Chou 13,000 sh (unchged)
John Hussman 2,000 sh (unchged)
David Dreman 1,321 sh (unchged)
Murray Stahl 28,302 sh (unchged)
Pioneer Investments 446,742 sh (-0.11%)
Jim Simons 5,702,700 sh (-4.41%)
» More
Q4 2016

AZN Guru Trades in Q4 2016

Ken Fisher 1,950,999 sh (-1.34%)
» More
» Details

Insider Trades

Latest Guru Trades with AZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:NYSE:LLY, OTCPK:BAYZF, OTCPK:GLAXF, NYSE:BMY, NYSE:ABBV, NYSE:SNY, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, OTCPK:GWPRF, NAS:HCM, OTCPK:HAWPF, OTCPK:MAYNF, NAS:AERI, AMEX:TXMD » details
Traded in other countries:AZN.Argentina, ZEG.Germany, AZNN.Mexico, AZN.Sweden, OXAZN.Switzerland, AZN.UK, AZNCF.USA,
AstraZeneca PLC is a biopharmaceutical company. It is engaged in the discovery and development of new products, which are then manufactured, marketed and sold.

AstraZeneca PLC was incorporated in England and Wales on June 17, 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company is engaged in the discovery and development of new products, which are then manufactured, marketed and sold. It is engaged in healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.

Top Ranked Articles about AstraZeneca PLC

Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Eli Lilly has new drugs in the pipeline that will replace its failed Alzheimer treatment
Eli Lilly (NYSE:LLY) made the news for the wrong reasons on Nov. 23 after announcing that its experimental treatment for Alzheimer’s drug, Solanezumab, had failed. If it had been successful, Eli Lilly would have the distinction of researching the first effective disease modifying drug in the world. Read more...
How Could a Potential Nexium Lawsuit Affect AstraZeneca? Company's top line could suffer significantly if Nexium sales are affected by lawsuit
AstraZeneca (NYSE:AZN) is the company behind Nexium, one of the world’s most successful drugs in terms of sales. Nexium, the brand name of esomeprazole, is a proton-pump inhibitor that reduces stomach acid. It was developed in the 1990s for the purpose of treating dyspepsia, peptic ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison syndrome. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 33.08
AZN's P/E(ttm) is ranked lower than
59% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. AZN: 33.08 )
Ranked among companies with meaningful P/E(ttm) only.
AZN' s P/E(ttm) Range Over the Past 10 Years
Min: 6.03  Med: 12.14 Max: 99.64
Current: 33.08
6.03
99.64
Forward P/E 13.19
AZN's Forward P/E is ranked higher than
67% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.95 vs. AZN: 13.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 33.08
AZN's PE(NRI) is ranked lower than
59% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. AZN: 33.08 )
Ranked among companies with meaningful PE(NRI) only.
AZN' s PE(NRI) Range Over the Past 10 Years
Min: 6.03  Med: 12.14 Max: 99.64
Current: 33.08
6.03
99.64
Price/Owner Earnings (ttm) 40.27
AZN's Price/Owner Earnings (ttm) is ranked lower than
61% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.46 vs. AZN: 40.27 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
AZN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.38  Med: 11.61 Max: 45.23
Current: 40.27
5.38
45.23
P/B 5.83
AZN's P/B is ranked lower than
79% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. AZN: 5.83 )
Ranked among companies with meaningful P/B only.
AZN' s P/B Range Over the Past 10 Years
Min: 2.3  Med: 3.77 Max: 6.97
Current: 5.83
2.3
6.97
P/S 3.46
AZN's P/S is ranked lower than
56% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.91 vs. AZN: 3.46 )
Ranked among companies with meaningful P/S only.
AZN' s P/S Range Over the Past 10 Years
Min: 1.61  Med: 2.4 Max: 4.03
Current: 3.46
1.61
4.03
PFCF 142.84
AZN's PFCF is ranked lower than
91% of the 200 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.43 vs. AZN: 142.84 )
Ranked among companies with meaningful PFCF only.
AZN' s PFCF Range Over the Past 10 Years
Min: 6.18  Med: 13.93 Max: 179.65
Current: 142.84
6.18
179.65
POCF 29.63
AZN's POCF is ranked lower than
72% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.46 vs. AZN: 29.63 )
Ranked among companies with meaningful POCF only.
AZN' s POCF Range Over the Past 10 Years
Min: 5.35  Med: 8.63 Max: 33.31
Current: 29.63
5.35
33.31
EV-to-EBIT 33.55
AZN's EV-to-EBIT is ranked lower than
73% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.56 vs. AZN: 33.55 )
Ranked among companies with meaningful EV-to-EBIT only.
AZN' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.3  Med: 8.5 Max: 64.7
Current: 33.55
4.3
64.7
EV-to-EBITDA 18.14
AZN's EV-to-EBITDA is ranked lower than
54% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.22 vs. AZN: 18.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
AZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.6  Med: 6.8 Max: 20.9
Current: 18.14
3.6
20.9
Shiller P/E 17.90
AZN's Shiller P/E is ranked higher than
87% of the 159 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 44.99 vs. AZN: 17.90 )
Ranked among companies with meaningful Shiller P/E only.
AZN' s Shiller P/E Range Over the Past 10 Years
Min: 10  Med: 13.52 Max: 20.23
Current: 17.9
10
20.23
Current Ratio 0.84
AZN's Current Ratio is ranked lower than
91% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. AZN: 0.84 )
Ranked among companies with meaningful Current Ratio only.
AZN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 1.48 Max: 2.03
Current: 0.84
0.64
2.03
Quick Ratio 0.68
AZN's Quick Ratio is ranked lower than
88% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. AZN: 0.68 )
Ranked among companies with meaningful Quick Ratio only.
AZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.54  Med: 1.25 Max: 2.03
Current: 0.68
0.54
2.03
Days Inventory 196.95
AZN's Days Inventory is ranked lower than
81% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. AZN: 196.95 )
Ranked among companies with meaningful Days Inventory only.
AZN' s Days Inventory Range Over the Past 10 Years
Min: 88.45  Med: 122.03 Max: 196.95
Current: 196.95
88.45
196.95
Days Sales Outstanding 100.38
AZN's Days Sales Outstanding is ranked lower than
69% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.25 vs. AZN: 100.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
AZN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 59.12  Med: 71.43 Max: 103.54
Current: 100.38
59.12
103.54

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.93
AZN's Dividend Yield is ranked higher than
95% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. AZN: 4.93 )
Ranked among companies with meaningful Dividend Yield only.
AZN' s Dividend Yield Range Over the Past 10 Years
Min: 2.22  Med: 4.59 Max: 7.64
Current: 4.93
2.22
7.64
Dividend Payout 1.44
AZN's Dividend Payout is ranked lower than
94% of the 389 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. AZN: 1.44 )
Ranked among companies with meaningful Dividend Payout only.
AZN' s Dividend Payout Range Over the Past 10 Years
Min: 0.37  Med: 0.46 Max: 2.89
Current: 1.44
0.37
2.89
Dividend Growth (3y) -1.80
AZN's Dividend Growth (3y) is ranked lower than
67% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.10 vs. AZN: -1.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
AZN' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -4.5  Med: 11.2 Max: 28.3
Current: -1.8
-4.5
28.3
Forward Dividend Yield 3.15
AZN's Forward Dividend Yield is ranked higher than
96% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. AZN: 3.15 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 5.41
AZN's Yield on cost (5-Year) is ranked higher than
88% of the 779 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.17 vs. AZN: 5.41 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
AZN' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.45  Med: 5.07 Max: 8.44
Current: 5.41
2.45
8.44
3-Year Average Share Buyback Ratio -0.50
AZN's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. AZN: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.3  Med: 1.8 Max: 4.9
Current: -0.5
-23.3
4.9

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.88
AZN's Price/Projected FCF is ranked higher than
62% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. AZN: 1.88 )
Ranked among companies with meaningful Price/Projected FCF only.
AZN' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.49  Med: 1.33 Max: 5.98
Current: 1.88
0.49
5.98
Price/Median PS Value 1.44
AZN's Price/Median PS Value is ranked lower than
68% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. AZN: 1.44 )
Ranked among companies with meaningful Price/Median PS Value only.
AZN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.76  Med: 1.29 Max: 2.48
Current: 1.44
0.76
2.48
Earnings Yield (Greenblatt) (%) 3.00
AZN's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. AZN: 3.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AZN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.5  Med: 11.7 Max: 23.1
Current: 3
1.5
23.1
Forward Rate of Return (Yacktman) (%) -15.86
AZN's Forward Rate of Return (Yacktman) (%) is ranked lower than
89% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.63 vs. AZN: -15.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AZN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -17.8  Med: 18.5 Max: 27.5
Current: -15.86
-17.8
27.5

More Statistics

Revenue (TTM) (Mil) $23,816
EPS (TTM) $ 0.97
Beta0.56
Short Percentage of Float0.97%
52-Week Range $25.55 - 35.04
Shares Outstanding (Mil)2,530.00

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 24,428 23,869 25,876 28,181
EPS ($) 2.06 1.94 2.55 2.77
EPS w/o NRI ($) 2.06 1.94 2.55 2.77
EPS Growth Rate
(3Y to 5Y Estimate)
1.41%
Dividends Per Share ($) 1.52 1.55 1.76 2.15
» More Articles for AZN

Headlines

Articles On GuruFocus.com
Dodge & Cox's Stock Fund 4th Quarter Commentary Jan 16 2017 
Big Alzheimer Flop Creates Buying Opportunity for Eli Lilly Dec 10 2016 
8 Uncommon Stocks NWQ Managers Is Buying Dec 06 2016 
How Could a Potential Nexium Lawsuit Affect AstraZeneca? Nov 03 2016 
Novo Nordisk Is Being Ignored Oct 06 2016 
Novartis Is Surviving Oct 03 2016 
10 Stocks Dodge & Cox Keep Buying Sep 22 2016 
Dividend and Value Opportunities in the Large-Cap Pharmaceutical Space Apr 05 2016 
Francis Chou Raises Stake in Resolute Forest Products Mar 20 2016 
Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 

More From Other Websites
FDA Track Record Bodes Well For Merck Keytruda Plus Chemo: Leerink Jan 17 2017
[$$] AstraZeneca expands trials for key cancer drug Jan 17 2017
6:57 am AstraZeneca provides update on its Immuno-Oncology late-stage clinical development programme... Jan 17 2017
Dodge & Cox's Stock Fund 4th Quarter Commentary Jan 16 2017
Bristol-Myers Threatens Merck's 'Head Start' In Lung Cancer: Analyst Jan 12 2017
European Pharma Shares Hammered After Trump Press Conference Attack Jan 12 2017
Bristol-Myers and AstraZeneca Take Beatings Jan 11 2017
2 Stocks For a Trump-ed Up Pharma Market Jan 11 2017
European stocks trim gains after Trump comments send drug stocks lower Jan 11 2017
Merck leapfrogs rivals in lung cancer drug combination race Jan 11 2017
Will Vectura Group plc outperform AstraZeneca plc after today’s results gain a Brexit boost? Jan 11 2017
Can AstraZeneca (AZN) Be a Solid Choice for Value Investors? Jan 10 2017
[$$] Chance for an agile new drug approval system Jan 09 2017
Mysterious $5 Billion Biotech Firm Moderna Lays Out Drug Pipeline Jan 09 2017
Bullish and Bearish Reversals in the Market Jan 09 2017
Shell, AstraZeneca Could Surprise in 2017, Credit Suisse Says Jan 05 2017
Here's Why General Motors Is One of Wednesday's Most Active Stocks Jan 04 2017
AstraZeneca PLC (ADR) (AZN) Planning Tagrisso Label Expansion To Shore Up Earnings Jan 03 2017
AstraZeneca CIO Makes IT Twice As Good At Half The Cost - Here Is How Jan 03 2017
Credit Suisse, AstraZeneca among top BofA-ML's top European picks for first quarter Jan 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)